BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, April 29, 2013
At least 21 biotechs and pharmas reported earnings
last week. While big biotechs Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)
and Biogen Idec Inc. (NASDAQ:BIIB) added $3.8 billion in aggregate
market value after posting EPS that beat the Street's estimates, Amgen Inc. (NASDAQ:AMGN)
and Celgene Corp. (NASDAQ:CELG) together gave back $3.1 billion. Celgene
also announced that pomalidomide missed the primary endpoint in the Phase III
RESUME trial to treat myeloproliferative-neoplasm-associated myelofibrosis (see
B17). Amgen beat the consensus EPS estimate, but revenues of $4.2 billion
were below the Street's estimate of $4.4 billion.
AbbVie Inc. (NYSE:ABBV) gained $5.5 billion in
market value after reporting earnings for the first time since being spun out
of Abbott Laboratories (NYSE:ABT) at the start of 2013. The pharma
reported EPS and revenues that beat the Street. Ironwood Pharmaceuticals
Inc. (NASDAQ:IRWD) fell 12% after reporting a loss per share and revenues
that missed the Street's estimates. Ironwood and partner Forest Laboratories
Inc. (NYSE:FRX) reported $4.5M in net sales in the first full quarter of
sales for gastrointestinal drug Linzess linaclotide, which was launched in
December 2012. (A) Fiscal 4Q earnings; Mcap in $M
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]